Impact of lymph node sparing on the anti-tumor response for head and neck cancer treated with radiation and immunotherapy
淋巴结保留对放射和免疫治疗头颈癌抗肿瘤反应的影响
基本信息
- 批准号:10449726
- 负责人:
- 金额:$ 12.42万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-04-01 至 2026-03-03
- 项目状态:未结题
- 来源:
- 关键词:AffectAgonistAnimal ModelAntigensAntitumor ResponseArchivesAutomobile DrivingB-LymphocytesBiological AssayBloodCD8B1 geneCancer ModelCancer PatientCanis familiarisCarcinomaCell DensityCellsClinicalClinical DataCombination immunotherapyDataDoseEuropeFlow CytometryGoalsHead and Neck CancerHumanImmuneImmune responseImmunityImmunohistochemistryImmunologicsImmunologyImmunotherapyInflammatoryLigandsLymph Node TissueMentorshipMetastatic Neoplasm to Lymph NodesMonoclonal AntibodiesMouth CarcinomaMusNatural Killer CellsNeoplasm MetastasisOX40Pathway interactionsPatient-Focused OutcomesPatientsPhenotypePhysiciansPopulationPre-Clinical ModelPrimary NeoplasmPrognosisProgram DevelopmentRadiationRadiation OncologistRadiation therapyRegulatory T-LymphocyteReportingResearchRodentRoleSamplingScientistSiteT cell responseT-Cell DepletionTestingTreatment outcomeTumor ImmunityUnited Statesadvanced diseaseanti-tumor immune responseantigen-specific T cellsbasecanine modelcareercareer developmentclinically relevantcomparativedesigndraining lymph nodeeffector T cellexperimental studyhead and neck cancer patienthigh riskimmunosuppressedimprovedimproved outcomeinnovationinterestirradiationlymph nodesmouse modelneoplasm immunotherapyneoplastic cellnovel strategiesnovel therapeuticspatient responsepre-clinicalradiation effectstandard of caretranscriptome sequencingtranslational cancer researchtranslational scientisttumortumor growthtumor microenvironment
项目摘要
Abstract
As a board-certified veterinary radiation oncologist and radiobiologist, I am committed to, and excited for, a
career in translational cancer research as a physician scientist. My long-term career goal is to develop into an
independent veterinary clinician scientist, proficient in designing and performing innovative radiation research,
with a focused interest in tumor microenvironmental effects of radiation therapy and immunotherapy to improve
treatment outcomes for patients with head and neck cancer.
Head and neck cancer (HNC) is common in the United States and Europe and the prognosis is poor for patients
with advanced disease. Stereotactic body radiation therapy (SBRT), which allows delivery of high dose, high
precision radiation in a few fractions, is a novel therapy that can be used to treat HNC patients. Evidence exists
that SBRT is a more potent activator of anti-tumor immune responses compared to conventional radiotherapy.
Emerging preclinical and clinical data suggest SBRT combined with immunotherapy has the potential to convert
immunologically “cold” (immunosuppressed) tumors into “hot” (inflamed) tumors. SBRT and IO combinations can
stimulate effector T cell responses to each patient’s tumor. HNC patients with high risks for lymph node
metastasis typically receive RT targeted to their primary tumor and regional lymph nodes (RLN) in order to
eradicate latent metastatic tumor cells; however, RLNs are critical sites for generating immune responses, and
RLN irradiation is likely to destroy the immune cells responsible for anti-tumor responses.
Based on my preliminary data that SBRT caused depletion of T cell density and expansion of
immunosuppressive immune cell populations in RLNs compared to RLNs spared from RT, we propose to study
how RLN irradiation affects local and systemic anti-tumor immunity when combined with RT and IO. We will test
our hypotheses with orthotopic murine head and neck cancer models and in canine cancer patients who have
developed oral carcinoma. For the study, we will use the local tumor immunotherapy combination of agonistic
OX-40 monoclonal antibody + TLR9 ligand, which has demonstrated positive tumor microenvironmental immune
effects in mice and dogs.
If we demonstrate RT+IO and RLN sparing improves outcomes in translational preclinical models of advanced
HNC, the results of this project would challenge the current standard of care and clinical paradigm surrounding
radiation, immunotherapy, and elective RLN irradiation for patients with advanced HNC. Through the K01 career
development program, I will have the opportunity to delve deeper into radiation and immunology research and
grow as an independent translational scientist through the direct influence, support, and guidance of my strong
mentorship team, Dr. Steven Dow, Dr. Xiao-Jing Wang, and Dr. Sana Karam.
摘要
作为一名委员会认证的兽医放射肿瘤学家和放射生物学家,我致力于并为之兴奋,
作为一名医生科学家从事转化癌症研究。我的长期职业目标是发展成为一名
独立兽医临床科学家,精通设计和执行创新的放射研究,
专注于放射治疗和免疫治疗的肿瘤微环境效应,以改善
头颈癌患者的治疗结果。
头颈部癌(HNC)在美国和欧洲很常见,患者预后很差
患有晚期疾病立体定向体部放射治疗(SBRT),其允许递送高剂量、高剂量的放射性物质。
在几个部分中的精确辐射是可用于治疗HNC患者的新颖疗法。证据存在
SBRT是一种比常规放疗更有效的抗肿瘤免疫反应激活剂。
新出现的临床前和临床数据表明,SBRT联合免疫治疗有可能转化为
免疫“冷”(免疫抑制)肿瘤转化为“热”(发炎)肿瘤。SBRT和IO组合可以
刺激效应T细胞对每个患者肿瘤的反应。淋巴结高风险HNC患者
转移瘤通常接受靶向其原发肿瘤和区域淋巴结(RLN)的RT,
根除潜伏的转移性肿瘤细胞;然而,RLN是产生免疫应答的关键部位,
RLN辐射可能会破坏负责抗肿瘤反应的免疫细胞。
根据我的初步数据,SBRT引起T细胞密度的耗竭和
免疫抑制免疫细胞群体的RLN相比,从RT幸免于RLN,我们建议研究
RLN照射与RT和IO联合时如何影响局部和全身抗肿瘤免疫。我们将测试
我们的假设与原位小鼠头颈癌模型和犬癌症患者谁有
发展成口腔癌对于本研究,我们将采用局部肿瘤免疫治疗联合激动剂
OX-40单克隆抗体+TLR 9配体,已证实肿瘤微环境免疫阳性
对小鼠和狗的影响。
如果我们证明RT+IO和RLN保留可以改善晚期乳腺癌转化临床前模型的结局,
HNC,该项目的结果将挑战当前的护理标准和临床范式,
放射治疗、免疫治疗和选择性喉返神经放射治疗晚期HNC患者。K 01职业生涯
发展计划,我将有机会深入研究辐射和免疫学研究,
成长为一个独立的翻译科学家通过直接影响,支持,和我的强大的指导
导师团队,Steven Dow博士,Xiao-Jing Wang博士和Sana Karam博士。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Mary-Keara Boss其他文献
Mary-Keara Boss的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Mary-Keara Boss', 18)}}的其他基金
Impact of lymph node sparing on the anti-tumor response for head and neck cancer treated with radiation and immunotherapy
淋巴结保留对放射和免疫治疗头颈癌抗肿瘤反应的影响
- 批准号:
10594506 - 财政年份:2022
- 资助金额:
$ 12.42万 - 项目类别:
相似国自然基金
Agonist-GPR119-Gs复合物的结构生物学研究
- 批准号:32000851
- 批准年份:2020
- 资助金额:24.0 万元
- 项目类别:青年科学基金项目
相似海外基金
S1PR1 agonistによる脳血液関門制御を介した脳梗塞の新規治療法開発
S1PR1激动剂调节血脑屏障治疗脑梗塞新方法的开发
- 批准号:
24K12256 - 财政年份:2024
- 资助金额:
$ 12.42万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
AHR agonistによるSLE皮疹の新たな治療薬の開発
使用 AHR 激动剂开发治疗 SLE 皮疹的新疗法
- 批准号:
24K19176 - 财政年份:2024
- 资助金额:
$ 12.42万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Evaluation of a specific LXR/PPAR agonist for treatment of Alzheimer's disease
特定 LXR/PPAR 激动剂治疗阿尔茨海默病的评估
- 批准号:
10578068 - 财政年份:2023
- 资助金额:
$ 12.42万 - 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
- 批准号:
10933287 - 财政年份:2023
- 资助金额:
$ 12.42万 - 项目类别:
Targeting breast cancer microenvironment with small molecule agonist of relaxin receptor
用松弛素受体小分子激动剂靶向乳腺癌微环境
- 批准号:
10650593 - 财政年份:2023
- 资助金额:
$ 12.42万 - 项目类别:
AMPKa agonist in attenuating CPT1A inhibition and alcoholic chronic pancreatitis
AMPKa 激动剂减轻 CPT1A 抑制和酒精性慢性胰腺炎
- 批准号:
10649275 - 财政年份:2023
- 资助金额:
$ 12.42万 - 项目类别:
A randomized double-blind placebo controlled Phase 1 SAD study in male and female healthy volunteers to assess safety, pharmacokinetics, and transient biomarker changes by the ABCA1 agonist CS6253
在男性和女性健康志愿者中进行的一项随机双盲安慰剂对照 1 期 SAD 研究,旨在评估 ABCA1 激动剂 CS6253 的安全性、药代动力学和短暂生物标志物变化
- 批准号:
10734158 - 财政年份:2023
- 资助金额:
$ 12.42万 - 项目类别:
Investigating mechanisms underpinning outcomes in people on opioid agonist treatment for OUD: Disentangling sleep and circadian rhythm influences on craving and emotion regulation
研究阿片类激动剂治疗 OUD 患者结果的机制:解开睡眠和昼夜节律对渴望和情绪调节的影响
- 批准号:
10784209 - 财政年份:2023
- 资助金额:
$ 12.42万 - 项目类别:
A novel nanobody-based agonist-redirected checkpoint (ARC) molecule, aPD1-Fc-OX40L, for cancer immunotherapy
一种基于纳米抗体的新型激动剂重定向检查点 (ARC) 分子 aPD1-Fc-OX40L,用于癌症免疫治疗
- 批准号:
10580259 - 财政年份:2023
- 资助金额:
$ 12.42万 - 项目类别:
Fentanyl Addiction: Individual Differences, Neural Circuitry, and Treatment with a GLP-1 Receptor Agonist
芬太尼成瘾:个体差异、神经回路和 GLP-1 受体激动剂治疗
- 批准号:
10534864 - 财政年份:2023
- 资助金额:
$ 12.42万 - 项目类别: